DNA Biomed Solns (DNA) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.003x

Based on the latest financial reports, DNA Biomed Solns (DNA) has a cash flow conversion efficiency ratio of -0.003x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-265.00K ≈ $-710.46 USD) by net assets (ILA82.79 Million ≈ $221.96K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of DNA Biomed Solns to measure how much of total assets are equity-financed.

DNA Biomed Solns - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how DNA Biomed Solns's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DNA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

DNA Biomed Solns Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of DNA Biomed Solns ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shengfeng Development Limited Class A Ordinary Shares NASDAQ:SFWL	-0.112x
Rekah Pharmaceutical Industry Ltd TA:REKA	0.037x
Fortune Bay Corp V:FOR	-0.022x
Impresa - Sociedade Gestora de Participações Sociais S.A LS:IPR	-0.174x
Denge Yatirim Holding AS IS:DENGE	-0.187x
Xreality Group Ltd AU:XRG	0.212x
Level Biotechnology TWO:3118	0.021x
Sharps Technology Inc NASDAQ:STSS	-0.017x

Annual Cash Flow Conversion Efficiency for DNA Biomed Solns (2013–2024)

The table below shows the annual cash flow conversion efficiency of DNA Biomed Solns from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see DNA Biomed Solns (DNA) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA101.47 Million ≈ $272.02K	ILA1.61 Million ≈ $4.32K	0.016x	+285.32%
2023-12-31	ILA79.19 Million ≈ $212.30K	ILA-678.00K ≈ $-1.82K	-0.009x	-93.75%
2022-12-31	ILA80.11 Million ≈ $214.76K	ILA-354.00K ≈ $-949.06	-0.004x	+89.70%
2021-12-31	ILA54.33 Million ≈ $145.66K	ILA-2.33 Million ≈ $-6.25K	-0.043x	+44.17%
2020-12-31	ILA7.95 Million ≈ $21.32K	ILA-611.00K ≈ $-1.64K	-0.077x	-57.74%
2019-12-31	ILA28.18 Million ≈ $75.56K	ILA-1.37 Million ≈ $-3.68K	-0.049x	-90.35%
2018-12-31	ILA64.90 Million ≈ $174.00K	ILA-1.66 Million ≈ $-4.45K	-0.026x	+7.16%
2017-12-31	ILA69.11 Million ≈ $185.27K	ILA-1.91 Million ≈ $-5.11K	-0.028x	-116.08%
2016-12-31	ILA-83.41 Million ≈ $-223.63K	ILA-14.30 Million ≈ $-38.34K	0.171x	-90.81%
2015-12-31	ILA-8.35 Million ≈ $-22.38K	ILA-15.57 Million ≈ $-41.73K	1.865x	+41.84%
2014-12-31	ILA-8.36 Million ≈ $-22.40K	ILA-10.99 Million ≈ $-29.45K	1.315x	+391.99%
2013-12-31	ILA11.49 Million ≈ $30.80K	ILA-5.17 Million ≈ $-13.87K	-0.450x	--

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$32.49 Million

ILA12.12 Billion ILA

Market Cap Rank

#23458 Global

#326 in Israel

Share Price

ILA98.40

Change (1 day)

-5.29%

52-Week Range

ILA86.00 - ILA147.50

All Time High

ILA1900.80